DEXA Bone Density: At-Home Options, Normal Ranges, and Optimal Targets

What Is a DEXA Scan and How Does It Measure Bone Density?

DEXA sends two low-dose X-ray beams at different energy levels through bone tissue. The difference in absorption between those two beams lets the scanner calculate bone mineral density (BMD) in grams per square centimeter. The lumbar spine (L1 through L4) and the proximal femur are the standard measurement sites because they predict fracture risk better than peripheral sites like the wrist or heel.

The radiation dose is extremely low. A standard DEXA scan delivers roughly 1 to 6 microsieverts, which is less than a single day of background radiation exposure and far below the 100 microsieverts from a chest X-ray. The International Society for Clinical Densitometry (ISCD) sets technical and reporting standards for DEXA across the world.

T-Scores vs. Z-Scores

The T-score compares your BMD to the peak bone mass of a healthy 30-year-old of the same sex. The Z-score compares you to an age-matched, sex-matched reference population. Clinicians use T-scores to diagnose osteoporosis and osteopenia in postmenopausal women and men over 50. They use Z-scores in premenopausal women, men under 50, and children, where comparing to same-age peers is more clinically meaningful.

How the WHO Classification Works

The World Health Organization published the definitive classification in 1994. According to that framework, a T-score at or above -1.0 is normal bone density; -1.0 to -2.5 (exclusive) is osteopenia; -2.5 or lower is osteoporosis; and -2.5 or lower with one or more fragility fractures is severe osteoporosis. The WHO diagnostic criteria remain the global standard used by every major endocrinology and rheumatology guideline.

Why the Femoral Neck Gets Special Weight

The femoral neck T-score carries extra clinical weight because hip fractures drive the highest mortality among osteoporotic injuries. A 2009 meta-analysis published in The Lancet and cited by the FRAX development group confirmed that femoral neck BMD predicted hip, vertebral, and total fracture risk more consistently than lumbar spine BMD alone across 12 prospective cohorts involving over 60,000 participants.

What Is the Optimal DEXA Bone Density Range?

Standard clinical guidelines define "normal" as a T-score above -1.0, but longevity medicine generally targets higher. Most preventive and functional medicine physicians aim for a T-score above -0.5 at both the hip and spine, which places bone density closer to peak young-adult values.

Standard Normal vs. Optimal

A T-score of 0.0 means your BMD matches the average peak bone mass of a 30-year-old. Scoring between 0.0 and -0.5 is considered excellent and aligns with the lowest fracture-risk tier in the FRAX model. Scoring between -0.5 and -1.0 is still technically normal but sits in a range where proactive lifestyle interventions (resistance training, calcium, vitamin D, protein sufficiency) produce measurable returns. The National Osteoporosis Foundation and the ISCD both endorse early lifestyle intervention well before the -2.5 treatment threshold is reached.

When Osteopenia Becomes Clinically Actionable

Not every T-score between -1.0 and -2.5 requires medication. The FRAX tool, developed by the WHO Collaborating Centre at the University of Sheffield, integrates BMD with age, sex, fracture history, glucocorticoid use, smoking, alcohol intake, rheumatoid arthritis, and parental hip fracture history. The U.S. National Osteoporosis Foundation recommends pharmacologic therapy for postmenopausal women with a 10-year major osteoporotic fracture probability at or above 20%, or a 10-year hip fracture probability at or above 3%, even when the T-score stays above -2.5.

Age and Sex Adjustments

Men and premenopausal women are classified differently. The ISCD 2019 Official Positions specify that osteoporosis in men under 50 should not be diagnosed on T-score alone; Z-score below -2.0 in this group should prompt investigation for secondary causes like hypogonadism, glucocorticoid excess, or malabsorption.

At-Home and Finger-Prick Alternatives to DEXA

No portable consumer device currently replicates central DEXA accuracy. A home DEXA scan does not exist in the way a home glucose meter does. Three practical categories of testing can extend monitoring between formal DEXA appointments.

Peripheral DEXA and Quantitative Ultrasound

Peripheral DEXA devices (pDXA) measure BMD at the wrist, finger, or heel and are sometimes found in pharmacies or community health fairs. Quantitative ultrasound (QUS) devices, which measure the heel, involve no radiation and cost less than $50 at some retail points. Both modalities can flag elevated fracture risk, but neither replaces central DEXA for diagnosis or treatment monitoring. A systematic review in Osteoporosis International found that heel QUS predicted hip fracture risk with relative risk estimates comparable to femoral neck BMD, making it a useful screening tool, not a diagnostic one.

Bone-Turnover Markers via Finger-Prick or Venipuncture

Two blood markers directly measure the speed of bone remodeling:

• CTX (C-terminal telopeptide of type I collagen): A resorption marker. High CTX signals accelerated bone breakdown. Fasting morning specimens are required because CTX varies up to 40% with food intake. The ISCD and IOF joint consensus endorses CTX and P1NP as the reference markers for monitoring antiresorptive therapy.
• P1NP (procollagen type I N-terminal propeptide): A formation marker. Low P1NP combined with high CTX is a classic pattern in active bone loss and is often seen in hypogonadal men on inadequately dosed testosterone replacement therapy.

Several direct-to-consumer lab services now offer CTX and P1NP through a finger-prick dried blood spot or standard venipuncture without a physician order in many U.S. States. Results typically return within 3 to 5 business days.

Vitamin D and Other Supportive Markers

Severe vitamin D deficiency (25-OH vitamin D below 20 ng/mL) independently accelerates bone loss by driving secondary hyperparathyroidism. The Endocrine Society's 2011 clinical practice guideline recommends maintaining 25-OH vitamin D at 30 ng/mL or above for bone health, with many longevity practitioners targeting 40 to 60 ng/mL. A finger-prick 25-OH vitamin D test is widely available, low cost, and should accompany any bone health evaluation.

A practical at-home bone health monitoring framework for adults not yet due for repeat DEXA looks like this: order fasting CTX and P1NP at months 3 and 6 after any medication or lifestyle change; check 25-OH vitamin D and PTH annually; recheck serum calcium and phosphate if PTH is elevated; and schedule repeat central DEXA at the interval your physician recommends (typically 1 to 2 years on pharmacotherapy, or 2 to 5 years off therapy).

Who Should Get a DEXA Scan and How Often?

Screening guidelines differ by sex, age, and risk profile. The U.S. Preventive Services Task Force (USPSTF) recommends DEXA for all women aged 65 and older, and for younger postmenopausal women whose 10-year fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors (roughly 9.3% on FRAX). The USPSTF found insufficient evidence to recommend universal screening in men, though the American College of Physicians recommends clinicians assess risk in men 65 and older and screen those with elevated risk.

High-Risk Groups Who Need Earlier Screening

Several conditions warrant DEXA before age 65 regardless of sex:

• Long-term glucocorticoid use (prednisone 5 mg/day or more for 3 months or longer)
• Primary hypogonadism or premature ovarian insufficiency
• Anorexia nervosa or other conditions causing sustained undernutrition
• Celiac disease, inflammatory bowel disease, or bariatric surgery affecting calcium absorption
• Aromatase inhibitor therapy for breast cancer
• Androgen deprivation therapy for prostate cancer

The American College of Rheumatology 2022 guidelines on glucocorticoid-induced osteoporosis specifically recommend baseline DEXA within 6 months of starting chronic steroid therapy, with annual follow-up scans.

Rescreening Intervals

A landmark study published in the New England Journal of Medicine in 2012 (N=4,957) found that women with normal bone density or mild osteopenia could safely wait 15 years before rescreening, while those with moderate osteopenia needed rescreening within 5 years and those with advanced osteopenia within 1 year. That evidence base informs the ISCD position that rescreening intervals should be individualized, not uniformly set at 2 years.

Understanding DEXA Results: Reading Your Report

A DEXA report includes T-scores and Z-scores at each measured site, a BMD value in g/cm², the reference database used, and often a Trabecular Bone Score (TBS) at modern facilities. Each element carries distinct clinical information.

Trabecular Bone Score

TBS is a texture-based index derived from the lumbar spine DEXA image that reflects bone microarchitecture quality independent of BMD. A TBS above 1.350 is considered normal; 1.200 to 1.350 is partially degraded; below 1.200 reflects degraded microarchitecture. A 2017 meta-analysis in JBMR (N=17,809 across 14 cohorts) found that TBS independently predicted major osteoporotic fracture after adjusting for BMD and FRAX score, with each standard deviation decrease in TBS associated with a 1.44-fold increase in fracture risk.

VFA: Vertebral Fracture Assessment

Many modern DEXA machines can perform Vertebral Fracture Assessment (VFA), a low-dose lateral spine scan done during the same appointment. The ISCD recommends VFA when T-score is below -1.0 combined with age over 70, height loss greater than 4 cm, or prior fracture history. Identifying a silent vertebral fracture automatically upgrades the clinical diagnosis to osteoporosis regardless of T-score.

Z-Score Interpretation Pitfalls

A Z-score at or above -2.0 is labeled "within the expected range for age" by the ISCD. That language sounds reassuring but can mask clinically significant bone loss in an older individual whose entire age cohort has poor BMD. Pairing the Z-score with the absolute BMD value and the FRAX calculation avoids misinterpretation.

Treatment Thresholds and Alendronate Indication

Pharmacotherapy is indicated when the fracture risk is high enough that the benefit-to-risk ratio of medication exceeds lifestyle intervention alone. Alendronate (70 mg weekly, oral) remains the most prescribed first-line agent worldwide.

DEXA Thresholds That Trigger Medication

The National Osteoporosis Foundation Clinician's Guide lists four indications for initiating pharmacotherapy in postmenopausal women and men over 50:

1. T-score at or below -2.5 at the lumbar spine or femoral neck
2. T-score between -1.0 and -2.5 with a 10-year major fracture probability at or above 20% via FRAX
3. T-score between -1.0 and -2.5 with a 10-year hip fracture probability at or above 3% via FRAX
4. Prior low-energy hip or vertebral fracture regardless of T-score

Alendronate Efficacy Data

The Fracture Intervention Trial (FIT), which enrolled 2,027 postmenopausal women with low femoral neck BMD, found that alendronate reduced the risk of vertebral fracture by 47% (relative risk 0.53, 95% CI 0.41 to 0.68, P<0.001) and hip fracture by 51% (relative risk 0.49, 95% CI 0.23 to 0.99) over 3 years compared to placebo. The full trial results were published in JAMA in 1996 and remain the cornerstone of bisphosphonate evidence.

The FDA-approved prescribing information for alendronate specifies that treatment is appropriate for osteoporosis (T-score at or below -2.5) and for glucocorticoid-induced bone loss in patients receiving prednisone 7.5 mg/day or more.

Drug Holidays and Long-Term Use

After 5 years of oral bisphosphonate therapy, the American Society for Bone and Mineral Research task force recommends reassessing fracture risk. Patients with a femoral neck T-score above -2.5 and no prior hip or vertebral fracture may take a drug holiday of 2 to 3 years while monitoring CTX every 6 to 12 months. Patients with ongoing high risk should continue therapy or transition to a different drug class such as denosumab or zoledronic acid.

Lifestyle Factors That Move the DEXA Score

Bone mineral density responds measurably to modifiable inputs over 12 to 24 months. The data below come from intervention trials, not observational associations.

Resistance Training

A meta-analysis of 49 randomized controlled trials in Osteoporosis International found that progressive resistance training increased lumbar spine BMD by 1.0% and femoral neck BMD by 0.9% per year in postmenopausal women compared to control. Heavier loads produced greater effect sizes. Two to three sessions per week of compound lower-body movements (squat, deadlift, step-up) targeting 70 to 85% of one-rep maximum showed the most consistent benefit.

Calcium and Vitamin D Sufficiency

Adequate calcium intake (1,000 to 1,200 mg/day from food and supplements combined for adults over 50) remains foundational. The NEJM Women's Health Initiative reanalysis (N=36,282) found that combined calcium plus vitamin D supplementation reduced hip fracture risk by 29% in adherent participants (relative hazard 0.71, 95% CI 0.52 to 0.97). Vitamin D3 doses of 800 to 2,000 IU daily maintain serum 25-OH levels at the target range in most adults, though absorption varies substantially by body weight and baseline status.

Protein Intake

Higher dietary protein correlates with higher BMD and lower fracture rates. A prospective analysis in the American Journal of Clinical Nutrition found that women in the highest quartile of protein intake had significantly lower rates of hip fracture over 12 years of follow-up compared to those in the lowest quartile (relative risk 0.31, 95% CI 0.12 to 0.80). Protein targets of 1.2 to 1.6 g/kg body weight per day align with both bone and muscle preservation goals in adults over 50.

Hormones and Bone Density: TRT and HRT Considerations

Sex hormones are among the most powerful regulators of bone remodeling. Both estrogen and testosterone suppress osteoclast activity; deficiency of either accelerates bone resorption.

Estrogen and Postmenopausal Bone Loss

The first 5 years after menopause can produce 2 to 3% annual bone loss at the spine due to declining estrogen. Menopausal hormone therapy (MHT) consistently preserves BMD across randomized trials. The Women's Health Initiative, reporting in JAMA (N=16,608), found that combined estrogen plus progestin reduced hip fracture incidence by 34% (hazard ratio 0.66, 95% CI 0.45 to 0.98) over 5.2 years. The Menopause Society (formerly NAMS) endorses MHT as an effective intervention for bone preservation in women under 60 or within 10 years of menopause onset.

Testosterone and Male Bone Health

Hypogonadal men lose bone mass at rates approaching postmenopausal women. A 36-month randomized trial published in JCEM found that testosterone replacement in men with documented hypogonadism increased lumbar spine BMD by 5.9% and femoral neck BMD by 2.6% compared to baseline (P<0.01 for both sites). The effect was largely mediated by aromatization of testosterone to estradiol, which explains why estradiol levels below 20 pg/mL in men on TRT are associated with ongoing bone loss even when total testosterone is optimized.